HEALTHCARE · BIOTECHNOLOGY

Roivant Sciences Ltd (ROIV) Stock Price, Analysis & Trade Signals

$36.28+0.12 (+0.33%)

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myastheni…

Market Cap
$26.21B
CEO
Matthew Gline
Employees
721
IPO Date
2020-12-08
Website
roivant.com

Tabs · Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics